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Breast cancer is a very common disease, aﬀ  ecting 
approximately one in nine women in the western world at 
some time in their lives. In recent years, passive 
immunotherapy has become an eﬀ  ective adjunct for the 
treatment of HER2/neu-overexpressing breast cancers 
that often respond well to agents such as trastuzumab. 
Th  is therapy is only eﬀ  ective, however, in a subset of 
breast cancers and patients with late-stage disease who 
are often immune suppressed are unlikely to respond. 
Furthermore, tumours can evolve to evade the immune 
response through regulatory T cells and myeloid 
suppressor cells [1,2]. Th  ere is therefore a need for a 
more globally eﬀ  ective, prophylactic vaccine.
Considerable eﬀ  ort has been directed towards this end, 
with limited success to date. A major problem with 
vaccine development is that the antigenic determinant 
ideally should be tumour speciﬁ  c. One such example is 
the glycoprotein mucin 1 (MUC-1), which is expressed 
by normal mammary epithelial cells. In cancer cells, 
however, the glycosylation pattern of MUC-1 is altered – 
rendering it antigenic [3]. Several promising 
MUC-1-based vaccines have been developed, although 
these have only been tested in a preclinical setting [4]. 
HER2 immunotherapy works because the density of the 
antigen is much higher in the cancer cells as a result of 
HER2 overexpression [5].
Th  e recent development of a prophylactic vaccine for 
cervical cancer [6] promises to save the lives of young 
women worldwide, particularly where screening pro  gram-
mes are unavailable. Breast cancer is much more likely to 
aﬀ  ect women than cervical cancer, and so the news that a 
prophylactic vaccine for breast cancer had been developed 
caused a media frenzy and was headline news.
Th   e cause of all this excitement was a paper published 
in  Nature Medicine by Jaini and coworkers [7]. Th  eir 
approach was based on the hypothesis that removal of an 
organ will provide protection against cancer developing 
in that organ. Th   is seems a simple, if somewhat dramatic, 
approach, and the breast is the only organ that perhaps 
could be induced to undergo catastrophic failure without 
severe consequences for the individual.
With this idea in mind, a protein speciﬁ  c for diﬀ  er-
entiated mammary epithelial cells was selected (α-
lactalbumin – a milk protein) and recombinant protein 
was used to immunise female mice. Interestingly, 
nonpregnant mice have few inﬂ  ammatory cells in their 
mammary tissue but lactating mice had inﬁ  ltrates of T 
cells and apparent lactation failure as pups failed to 
thrive, suggesting that the T cells had a cytotoxic eﬀ  ect. A 
more comprehensive follow-up of these animals would 
have provided reassurance that they did not suﬀ  er from 
detrimental eﬀ   ects arising from the extensive 
inﬂ  ammation in their mammary tissue, particularly since 
milk proteins are expressed in the gland with every 
oestrus cycle.
Th  e next step was to test whether immunisation with 
α-lactalbumin could provide prophylactic protection 
against mammary cancer. Young mice harbouring an 
MMTV-Neu oncogene were therefore immunised, and 
tumour growth was then monitored after 8 months. 
Although the numbers of mice are small, the vaccine was 
100% eﬀ  ective. It would have been worthwhile following 
the immunised animals for longer to conclude that they 
did not develop cancer later. Nevertheless, these data 
suggest that immunisation can provide protection from 
breast cancer.
Abstract
Cancer vaccines are the Holy Grail for patients 
and clinicians alike. The possibility that we can be 
vaccinated against common cancers is very appealing 
and the socioeconomic consequences are signifi  cant. 
A recent paper from Vincent Tuohy’s group, published 
in the journal Nature Medicine, suggests a new 
approach for the development of a prophylactic 
vaccine for breast cancer. Their strategy was to induce 
mammary gland failure in mice by immunisation with 
an antibody specifi  c to a milk protein that resulted in 
autoimmunity during lactation. This also showed some 
effi   cacy as a therapeutic vaccine. Can we look forward 
to the elimination of breast cancer?
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© 2010 BioMed Central LtdIn a diﬀ  erent tumour model – transplanted 4T1 cells – 
tumour growth was reduced in terms of size but not 
delayed in onset if immunisation occurred 13 days before 
tumour cell inoculation. Th  e focus of the work then 
turned to the potential therapeutic ability of α-
lacatalbumin immunisation to inhibit the growth of 
already established tumours. Inoculation of 4T1 cells 
followed by immunisation decreased the eﬀ  ectiveness of 
the vaccine considerably, and a gap of 21 days between 
inoculation and immunisation resulted in no signiﬁ  cant 
protection. If the experiments had been continued for 
longer than 32 days, it seems very likely that there would 
be no real diﬀ  erence between the immunised mice and 
mock-immunised mice in terms of tumour burden.
Could this be an exciting prophylactic vaccine? In 
comparison with the vaccine for cervical cancer, which is 
primarily given to teenage girls, we suspect that most 
young women would not be willing to avoid lactation as 
the authors suggested – this is a natural consequence of 
pregnancy. Is it likely that women would not breast feed 
their infants in order to avoid a cancer that they have a 
10% chance of developing 30 years later? Th   is approach is 
therefore unlikely to be adopted as a prophylactic vaccine. 
Could it be useful for therapeutic purposes? Th  at  depends 
on the expression of α-lactalbumin by breast cancer cells, 
particularly the cancer-initiating (stem) cells, since 
eliminating the bulk of the tumour and not the cancer 
stem cells will not prevent recurrence of the tumour.
Whether α-lactalbumin is expressed in human breast 
cancers is not clear as the mRNA has not been identiﬁ  ed 
in breast cancer samples [8] and – as shown in this key 
publication by Hall and colleagues – there is a peptide 
that shares antigenic determinants with α-lactalbumin 
and with which antibodies to α-lactalbumin immuno-
react. Bailey and colleagues, using a well-characterised 
antibody, could not detect α-lactalbumin in human 
breast cancers [9], whilst it was present in pregnant 
breast and in lactational foci seen in normal virgin 
women taking oral contraceptives. Current data on α-
lactalbumin expression are based on contradictory data 
that are now nearly three decades old. Th  ere  is  suﬃ   cient 
uncertainty regarding the expression of α-lactalbumin in 
both the normal breast and breast cancers to question 
the validity of considering α-lactalbumin as a vaccine 
target in humans.
It is unfortunate that this preliminary study should be 
the subject of such unrealistic press coverage in such an 
emotive arena.
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